Cite
LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
MLA
Qin, S., et al. “LBA36 Final Analysis of RATIONALE-301: Randomized, Phase III Study of Tislelizumab versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma.” Annals of Oncology, vol. 33, Sept. 2022, pp. S1402–03. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.08.033.
APA
Qin, S., Kudo, M., Meyer, T., Finn, R. S., Vogel, A., Bai, Y., Guo, Y., Meng, Z., Zhang, T., Satoh, T., Hiraoka, A., Marino, D., Assenat, E., Wyrwicz, L., Campos, M. C., Hsing-Tao, K., Boisserie, F., Li, S., Chen, Y., & Zhu, A. X. (2022). LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Annals of Oncology, 33, S1402–S1403. https://doi.org/10.1016/j.annonc.2022.08.033
Chicago
Qin, S., M. Kudo, T. Meyer, R.S. Finn, A. Vogel, Y. Bai, Y. Guo, et al. 2022. “LBA36 Final Analysis of RATIONALE-301: Randomized, Phase III Study of Tislelizumab versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma.” Annals of Oncology 33 (September): S1402–3. doi:10.1016/j.annonc.2022.08.033.